Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Higher Seroprevalence of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies Among Racial Minorities in the United States

4 Dec 2021

Abstract excerpt

Anti-adeno-associated viral vector (AAV) neutralizing antibodies (NAbs) can ablate efficacy of transgene expression following intravenous vector administration. This observation in both preclinical and clinical trials has led to exclusion of NAb-positive patients from receiving AAV gene therapy. AAV drug development includes selection of capsids with lower NAb seroprevalence that also possess other favorable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34861783
DOI: 10.1089/hum.2021.243

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Higher Seroprevalence of Anti-Adeno-Associated Viral Vector Neutralizing Antibodies Among Racial Minorities in the United StatesPMID 34861783Read ↗

Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapiesSemantic proximity Read ↗

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacsSemantic proximity Read ↗

Understanding AAV vector immunogenicity: from particle to patientSemantic proximity Read ↗

High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypesSemantic proximity Read ↗

Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapySemantic proximity Read ↗

Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler–Najjar SyndromeSemantic proximity Read ↗

Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After TrialSemantic proximity Read ↗

Seroprevalence of adeno-associated virus types 1, 2, 3, 4, 5, 6, 8, and 9 in a Basque cohort of healthy donorsSemantic proximity Read ↗

Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular DystrophySemantic proximity Read ↗

Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population CohortSemantic proximity Read ↗

Worldwide Epidemiology of Neutralizing Antibodies to Adeno‐Associated VirusesSemantic proximity Read ↗

Adeno-Associated Virus Antibody Profiles in Newborns, Children, and AdolescentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.